Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-24T12:11:59.706Z Has data issue: false hasContentIssue false

How to Perform Translocator Protein PET-CT Scanning for Microglial Activation in Schizophrenia Patients.

Published online by Cambridge University Press:  15 April 2020

L. De Picker
Affiliation:
Collaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium
S. Staelens
Affiliation:
Molecular Imaging Centre Antwerp, University of Antwerp, Antwerp, Belgium
S. Ceyssens
Affiliation:
Nuclear Medicine, University Hospital Antwerp, Antwerp, Belgium
J. Verhaeghe
Affiliation:
Molecular Imaging Centre Antwerp, University of Antwerp, Antwerp, Belgium
S. Deleye
Affiliation:
Molecular Imaging Centre Antwerp, University of Antwerp, Antwerp, Belgium
S. Stroobants
Affiliation:
Nuclear Medicine, University Hospital Antwerp, Antwerp, Belgium
B. Sabbe
Affiliation:
Collaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium
M. Morrens
Affiliation:
Collaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Activated microglia express translocator protein (TSPO) on the outer mitochondrial membrane. PET ligands targeting TSPO allow in vivo non-invasive visualization and quantification of neuroinflammation. Whereas inflammation in schizophrenia was previously studied using 11C-PK11195, 18F-PBR111 is a novel second-generation tracer, with high specific TSPO binding and longer half-life.

Objective

To establish a protocol for 18F-PBR111 TSPO PET in schizophrenia.

Methods

A pilot study on a Siemens Biograph mCT PET-scanner in healthy controls and schizophrenia patients (n=9).

Results

Subjects underwent a 90-minute dynamic brain PET-CT, following i.v. bolus injection of 214±13 MBq 18F-PBR111. An arterial input function was measured using continuous blood sampling (Twilite, Switzerland) with discrete samples for metabolite analysis. The metabolite corrected plasma input function (IPF) was calculated from the whole blood input function, individual plasma to whole blood and parent fraction data as determined by a SEP-PAK procedure. Dynamic PET data were reconstructed and a post-reconstruction motion correction was applied. Regional tissue time activity curves (TACs) were extracted from the PET images for regions of interest determined from individual MRI images. Total volume of distribution (VT) was then calculated from fitting a reversible two-tissue compartmental model to the measured TACs using the individual IPF. Prior genotyping for TSPO receptor polymorphism (rs6971) allowed to exclude low-affinity binders (estimated 10% of European population). The procedure was well tolerated.

Conclusions

We established a protocol for 18F-PBR111 TSPO PET in healthy subjects and schizophrenia patients, thereby providing useful information for others considering 18F-PBR111 TSPO PET imaging for evaluation of neuroinflammation.

Type
Article: 1489
Copyright
Copyright © European Psychiatric Association 2015
Submit a response

Comments

No Comments have been published for this article.